Theravance Biopharma Inc. and Mylan NV reported that revefenacin, a nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), met the primary endpoints in twin phase III studies, demonstrating statistically significant improvements from baseline over placebo in trough forced expiratory volume in one second (FEV1) after 12 weeks of dosing for each of two doses studied.